

**VIVALIS WILL PARTICIPATE IN THE SMALL CAP EVENT
IN PARIS ON APRIL 21 AND 22, 2008**

Nantes (France) – April 14, 2008

VIVALIS (Euronext Paris: VLS) is a public biopharmaceutical company that provides innovative cell-based solutions for the industrial manufacture of viral vaccines and therapeutic proteins, and develop drugs for the prevention of viral diseases. VIVALIS will attend the Small cap event in Paris on April 21 and 22 in "Hotel Hilton, 18 avenue de Suffren".

2008 will be a key period in the development of the company, for the technological success of its EBx[®] cell line as well as for its commercial and financial situation.

VIVALIS' contribution to this Forum is a way of strengthening its relationships with investors and the mean of increasing its visibility among the financial community. The Small cap event will give Funds managers the possibility to meet Franck Grimaud, VIVALIS' CEO, and deepen their knowledge of the company and its market.

Next press release:

April 16, 2008, after closure of the Euronext Paris market: quarterly report for the 1st quarter of 2008

About VIVALIS (www.vivalis.com)

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS's expertise and intellectual property are exploited in three main areas:

1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EBx[®] embryonic stem cell lines to pharmaceutical and biotechnology companies for the production of viral vaccines.
2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses its EBx[®] embryonic stem cell lines for the production of recombinant proteins to biotechnology and pharmaceutical companies.
3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established numerous partnerships with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Kaketsuken, Merial and SAFB Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES cluster of competitive excellence.

Euronext Paris Compartment C - FR0004056851
Reuters: **VLS.PA** – Bloomberg: **VLS FP**

Investor relations:

VIVALIS

Franck Grimaud, C.E.O.
Email: investors@vivalis.com

NewCap

Financial Communication Agency
Steve Grobet / Emmanuel Huynh
Tel.: +33 (0) 1 44 71 94 91
Email: vivalis@newcap.fr